000282689 001__ 282689
000282689 005__ 20240229155045.0
000282689 0247_ $$2doi$$a10.1016/j.pmedr.2023.102368
000282689 0247_ $$2pmid$$apmid:37680853
000282689 0247_ $$2pmc$$apmc:PMC10480621
000282689 0247_ $$2altmetric$$aaltmetric:153035656
000282689 037__ $$aDKFZ-2023-01835
000282689 041__ $$aEnglish
000282689 082__ $$a610
000282689 1001_ $$aWaheed, Dur-E-Nayab$$b0
000282689 245__ $$aAn update on one-dose HPV vaccine studies, immunobridging and humoral immune responses - A meeting report.
000282689 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2023
000282689 3367_ $$2DRIVER$$aarticle
000282689 3367_ $$2DataCite$$aOutput Types/Journal article
000282689 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1694183859_27134
000282689 3367_ $$2BibTeX$$aARTICLE
000282689 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282689 3367_ $$00$$2EndNote$$aJournal Article
000282689 520__ $$aThe 12th HPV Prevention and Control meeting was held on June 2-3, 2022, in Antwerp, Belgium. This technical meeting focused on several topics. This report summarises the discussions and lessons learned on two topics: an update on one-dose HPV vaccination studies and humoral immune responses upon HPV vaccination. Long-term follow-up studies from Costa Rica (eleven years) and India (ten years) report stable levels of antibodies after a single HPV vaccination. High vaccine effectiveness against incident persistent HPV 16/18 infection was seen in India (95.4%, 85.0-99.9) ten years postvaccination and in Kenya (97.5%, 81.7-99.7) eighteen months postvaccination, an important observation in a setting with a higher HPV prevalence. The potential impact of HPV vaccination using a one-dose schedule in India was modelled and showed that implementation of one-dose schedule can contribute towards achieving WHO Cervical Cancer elimination goals. These data support the WHO SAGE recommendations for adopting a one-dose schedule for females aged 9-20 years. Immunobridging studies were discussed during the meeting. General agreement was reached that when thoughtfully applied, they can support and accelerate the expanded use of HPV vaccine with new vaccine schedules, age cohorts, or vaccine formulations. Internationally standardised measurements of HPV immune responses important for the progress of HPV vaccinology field. Humoral immune responses upon HPV vaccination plateau at 24 months regardless of number of doses, therefore, data should be analysed after at least 24 months of follow-up to bridge studies accurately.
000282689 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000282689 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000282689 650_7 $$2Other$$aClinical trials
000282689 650_7 $$2Other$$aHuman papilloma virus
000282689 650_7 $$2Other$$aHumoral immune responses
000282689 650_7 $$2Other$$aImmunobridging
000282689 650_7 $$2Other$$aMeeting report
000282689 650_7 $$2Other$$aOne dose
000282689 650_7 $$2Other$$aSchedule
000282689 650_7 $$2Other$$aVaccination
000282689 7001_ $$aBurdier, F Ricardo$$b1
000282689 7001_ $$aEklund, Carina$$b2
000282689 7001_ $$aBaussano, Iacopo$$b3
000282689 7001_ $$0P:(DE-HGF)0$$aMariz, Filipe Colaço$$b4
000282689 7001_ $$aTéblick, Laura$$b5
000282689 7001_ $$aMugo, Nelly$$b6
000282689 7001_ $$aWatson-Jones, Deborah$$b7
000282689 7001_ $$aStanley, Margaret$$b8
000282689 7001_ $$aBaay, Marc$$b9
000282689 7001_ $$aVorsters, Alex$$b10
000282689 773__ $$0PERI:(DE-600)2785569-7$$a10.1016/j.pmedr.2023.102368$$gVol. 35, p. 102368 -$$p102368$$tPreventive Medicine Reports$$v35$$x2211-3355$$y2023
000282689 909CO $$ooai:inrepo02.dkfz.de:282689$$pVDB
000282689 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000282689 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000282689 9141_ $$y2023
000282689 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-18
000282689 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-18
000282689 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-18
000282689 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-18
000282689 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPREV MED REP : 2022$$d2023-10-26
000282689 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000282689 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000282689 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000282689 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:49:21Z
000282689 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:49:21Z
000282689 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T14:49:21Z
000282689 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000282689 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000282689 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-26
000282689 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-26
000282689 9201_ $$0I:(DE-He78)F035-20160331$$kF035$$lF035 Tumorvirus-spez. Vakzinierungsstrategie$$x0
000282689 980__ $$ajournal
000282689 980__ $$aVDB
000282689 980__ $$aI:(DE-He78)F035-20160331
000282689 980__ $$aUNRESTRICTED